Adicet Bio, Inc. announced that the FDA cleared its IND amendment to evaluate ADI-001 in patients with idiopathic inflammatory myopathy and stiff person syndrome, with plans to start enrollment in early 2025 as part of a Phase 1 trial involving multiple autoimmune diseases.